The heart function assessment registry trial in Saudi Arabia (HEARTS) is the first multicentre national quality improvement initiative in the Arab population to study the clinical features, management, and outcomes of inpatients admitted with acute heart failure (AHF) and outpatients with high-risk chronic heart failure (HCHF).
Introduction
Heart failure (HF) is a major cause of morbidity and mortality worldwide and has a significant negative impact on quality of life, health-care costs, and longevity. 1 -3 In Europe, .1 million hospitalizations have been attributed to acute episodes of HF each year. 4, 5 The cost for HF in the USA is estimated at $37 billion due to age-related increases in prevalence and readmission rates, despite advances in medical care. 6 The disease management approach views HF as a chronic illness spanning the home as well as outpatient and inpatient settings. Most HF patients have multiple medical, social, and behavioural challenges, and effective care requires a multidisciplinary approach that addresses these various difficulties.
Observational studies and randomized-controlled trials have shown that disease management programmes can reduce the frequency of hospitalization and improve the quality of life and functional status of HF patients. 7, 8 However, most studies on HF epidemiology, treatment, and outcomes have been performed in North America and Europe, and scarce data are available in Arab populations, which have different ethnic and cultural backgrounds. 9, 10 The heart function assessment registry trial in Saudi Arabia (HEARTS) is the first multicentre survey conducted in the Kingdom of Saudi Arabia and the Arab population to study the clinical features, management, and shortand long-term outcomes of patients with acute heart failure (AHF) and high-risk chronic heart failure (HCHF). The HEARTS study also involves a quality improvement initiative that aims to identify 'knowledge-care' gaps and potentially improve the outcomes of these patients. Here, we report the overall design and rationale of the study, in addition to the preliminary results of the pilot phase.
Methods
HEARTS is a prospective registry and quality improvement initiative comprising consecutive inpatients and high-risk outpatients with HF aged 18 years or older. Ethics committees at each hospital approved the study.
Study design
The study was divided into three phases:
(1) Pilot phase: The current report describes the results of this phase, which aimed to identify the logistic challenges that will be faced during the study and test the feasibility of completing the Case Report Forms (CRF) in 'real-life' practice. (2) Phase 1: This phase will measure the baseline clinical features and management practices and involve wider national representation of the health-care sectors in the country. The phase will last for 1 year and include the following quality improvement initiatives:
(a) Online access to each hospital's own 'real-life' data in order to discover 'knowledge-care' gaps early in the study and allow for timely improvement in clinical practice. (b) Quality indicators (QIs), which will be decided upon by the study co-investigators at the end of this phase based on the clinical care variables that require further improvement. Subsequently, the results of these QIs will be distributed to each individual hospital along with comparisons to other hospitals in the form of 'Report Cards'. Benchmarks for achieving these QIs will be distributed to the hospitals in the form of posters and pocket cards, in addition to standard admission orders and protocols. (3) Phase 2: This phase will start 6 months after the end of phase 1 and measure the same data variables to assess the effectiveness of these initiatives in improving the quality of care.
Study population † Acute heart failure: Patients admitted to the hospital [coronary/ intensive care units (CCU/ICU) or ward)] with acute HF, whether de novo or acute on chronic HF, who require treatment with intravenous diuretics, inotropes, or vasodilators. † High-risk chronic heart failure: Patients at high-risk for hospital re-admission and/or death who are referred to the heart failure clinic (HFC) according to one or more of the following criteria: † Severe left ventricular (LV) dysfunction and persistent HF symptoms (ejection fraction (EF) ,30% and persistent New York Heart Association (NYHA) class III or IV). † Heart failure associated with severe valvular heart disease. † Heart failure associated with significant renal impairment (creatinine.2 mg/dL ¼ 176 mm/L). † Poor tolerance or non-adherence to therapeutic regimens, or inadequate social or economic support. † Difficulty in up-titration of medications due to hypotension or other causes. † Multiple (≥2) hospitalisations and/or emergency department (ED) visits in the last year with HF exacerbation. Heart failure clinics were established in two of the tertiary care hospitals involved in the registry, with a maximum of two clinics per week. The clinics are led by a HF cardiology consultant with the involvement of other staff, including qualified HF nurse practitioners, clinical pharmacists, dieticians, physiotherapists, physician assistants, and nurse coordinators. The multidisciplinary team aims for adherence to clinical guidelines and potentially reducing re-hospitalisation and mortality, which includes a proper assessment of the functional class and quality of life of HF patients, up-titration of medical therapies, evaluation of cardioverter defibrillator (ICD)/cardiac resynchronization therapy (CRT) indications, frequent in-hospital follow-up appointments if clinically required, and education about lifestyle behaviours, such as healthy diet and exercise suitable for HF patients. Patients living outside the city were excluded because of the difficulty in providing regular clinic follow-up assessments for such patients. This report focuses on the clinical features and treatment strategies of HCHF patients upon admission to the HFC. The short-and long-term outcomes after admission to the clinic will be reported in subsequent reports of this registry.
Study organization
A CRF was filled out online (www.hearts-ksa.com) for each patient throughout their hospital stay by dedicated research assistants, physicians, and/or trained HFC nurses working in each hospital using standard definitions. A log book was completed for all patients in each hospital and ensured enrolment of .95% of consecutively admitted patients. All CRFs were verified by a cardiologist and sent to the principal co-ordinating centre, where the forms were checked for incomplete data and mistakes before submission for final analysis. To avoid double-counting patients, each patient's national identification number was used.
Data variables on the case report form
The diagnosis of HF and other definitions were based on the American College of Cardiology/American Heart Association key data elements and definitions for measuring the clinical management and outcomes of patients with chronic HF and the European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic HF. 3, 11 In particular, coronary artery disease (CAD) was diagnosed if any of the following conditions was present: at least one major epicardial coronary artery with .70% obstruction by coronary angiography, history of acute myocardial infarction associated with wall motion abnormality by echocardiography or gated blood pool imaging, and/ or stress testing (with or without imaging) diagnostic of CAD. Idiopathic dilated cardiomyopathy was diagnosed if HF was associated with reduced systolic function but without evidence of CAD, hypertension, primary valvular disease, myocardial infiltrative disease, Design and preliminary results of the Heart Function Assessment Registry Trial hypertrophic cardiomyopathy, toxins, pregnancy, or thyroid-related cardiomyopathy. Recurrent congestive HF in AHF patients was defined as patients who were managed initially out of their congestive state, who then developed in-hospital recurrence of symptoms and signs of congestive HF requiring restarting of intravenous diuretics, inotropes, or vasodilators. The following data were collected: patient demographics, clinical presentation, past medical history, laboratory investigations, medical therapies, cardiac procedures, and in-hospital outcomes, including mortality. Echocardiographic data were assessed by the daily-practising specialized cardiology consultants who were certified in echocardiography, a core laboratory was not used for data interpretation. Thirty-day and 1-year follow-up will be done in phases 1 and 2 and includes: death, NYHA class, hospital re-admission for HF, and use of diuretics, angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARBs), beta-blockers, aldosterone antagonists, an ICD, or CRT.
Statistical methods
Baseline characteristics including risk factor profiles as well as clinical history and in-hospital management were summarized for patients with AHF and HCHF separately. In-hospital course and patient outcome of all AHF patients were also summarized. Continuous variables that are normally distributed were summarized using mean and standard deviation while those not normally distributed were presented as median and interquartile range (IQR). Categorical variables were summarized using frequency and percentages. Data were entered and analysed using SPSS version 17 (SPSS Inc., USA). were either current or ex-smokers, and 36.4% had hyperlipidaemia. Atrial fibrillation or flutter was found on clinical presentation in 18% of patients, wide QRS (≥120 ms) was observed in 11.6% of patients, median + IQR values of N-terminal pro-brain natriuretic peptide (NT-proBNP) were 4616 + 5971 pg/mL, and positive serum troponin was measured in 30% of patients. Admission to the CCU/ICU occurred for 49% of patients with a median + IQR stay of 5 + 6 days in the CCU/ICU and 8 + 10 days for the total in-hospital stay. Most patients (92%) were treated with intravenous furosemide boluses and 48.3% with infusion. Intravenous nitrates were used in 21.3% of patients, dopamine in 17.2%, dobutamine in 11.6%, milrinone in 2.4%, levosimendan in 0.4%, and nesiritide in 0.4%. Echocardiography revealed that 27.5% of patients had preserved LV function (EF .40%), and 72.5% had moderate/severe LV dysfunction (EF ≤40%). Coronary angiography was performed during the hospital stay in 31.6% of patients. Figure 1 shows the high use of oral diuretics, beta-blockers, and ACE-I/ARBs before hospital admission, which increased at hospital discharge. Aldosterone blockers were used in 38% of patients and digitalis in 24%. Table 2 shows the in-hospital course, outcomes, and 30-day mortality. In-hospital recurrent congestive HF occurred in 26.2% of patients, cardiogenic shock in 8.3%, atrial fibrillation in 5%, and ventricular tachycardia or fibrillation in 2.6%. In-hospital mortality was 5.3%, and reached 7.5% 30 days after hospital discharge.
High-risk chronic heart failure
The mean age + SD of the outpatients with HCHF was 56.9 + 15.5 years, 71.7% were men, and 95.3% were Saudis. Cardiovascular risk factors included diabetes mellitus (53%), hypertension (74%), and smoking (43%) ( Table 2 In-hospital course of acute heart failure patients
Recurrent congestive heart failure 189 (26. Design and preliminary results of the Heart Function Assessment Registry Trial Figure 2 shows the high rate of evidence-based therapies in this patient cohort upon initial evaluation in the HFC. The most frequently used beta-blocker was bisoprolol (47.0%), followed by carvedilol (45.6%); the most frequent ACE-I was lisinopril (48.6%), followed by enalapril (4.4%) and perindopril (2%); and the most frequent ARB was candesartan (23%), followed by irbesartan (2.7%).
Discussion
Data about HF in the Arab population are scarce, and mainly originate from single-centre studies, with limited sample size. In a retrospective study of 155 non-valvular HF patients in Egypt, 66% had systolic HF, with hypertension, CAD, and diabetes mellitus being the predominant risk factors in this population. 9 In a registry of 1164 patients with HF from Oman, the most common causes of HF were ischaemia (51.7%), hypertension (24.9%), and idiopathic (8.3%), with valvular causes being the least common. 10 HEARTS is the first national multicentre registry and quality improvement initiative for both AHF and HCHF patients, not only in Saudi Arabia, but in the Arab population. This pilot report provides a reasonable snapshot of the clinical care of consecutive patients managed in major tertiary care hospitals. The study involved four out of six major health-care sectors (Ministry of Health, University, Security Forces, and Military) in three of the five main geographic areas of the country. We made several unique findings compared with other international registries. The average age of our acute and chronic HF patients was 57 -60 years, which is almost 10 years younger than their counterparts in developed countries. 12 -18 Even more alarming is the fact that 44.7% of our AHF patients had a history of chronic HF in the past, suggesting an earlier age of onset in many of our patients. This earlier onset is likely related to the extremely high prevalence of CAD risk factors in our population, 19 -21 in addition to the potential for a selection bias in referring relatively healthier and younger patients to the tertiary care hospitals involved in the study. In AHF patients, the prevalence of diabetes mellitus was 60.7%, which is at least double the rate reported in other AHF registries, 12 -18 whereas the rate of hypertension (70%) was similar despite the much younger age of our patients. Similar findings were also made in HCHF patients, but with lower rates of diabetes mellitus and higher rates of hypertension than in AHF patients. Plausible explanations for this high rate of CAD risk factors include lack of regular exercise and adopting a diet high in calories and fat content. 19 -22 Country-wide primary prevention programmes are urgently needed to reduce the high burden of CAD risk factors. Coronary artery disease was the main aetiology (50%) in our AHF patients, which is comparable to the rates reported in the recent ESC-HF pilot survey, 23 ADHERE, 12 -14 and OPTIMIZE-HF 16 registries, but higher than the one-third rate reported in the EHFS 17 and Japanese ATTEND registry. 18 The proportion of women in our study population (around one-third) was comparatively less than in other registries (up to one-half), which is likely related to females typically being affected by CAD at an average higher age than our study population. Our AHF patients had a lower median systolic blood pressure (125 mmHg) on clinical presentation than the median range of 135-141 mmHg in other studies, and almost three-quarters of our patients had moderate/severe LV dysfunction compared with one-half in the other studies. 12 -18 This difference is likely related to the fact that ACS was an exacerbating factor in over one-third of our AHF patients. In addition, we previously showed that patients with ST-segment elevation myocardial infarction tend to present late to the hospital, have delayed thrombolytic therapy, and are less likely to be treated with primary percutaneous coronary intervention compared with patients in developed countries. 24 The very low transfer rate (6.8%) of AHF patients by the ambulance services is one of the major factors for such delayed presentation and subsequently higher rates of myocardial injury and severe LV dysfunction. The overall rates of intravenous and oral therapies for AHF patients were reasonably satisfactory according to the guideline recommendations, including the low use of intravenous inotropes. 2, 3 This might have been one of the reasons behind the low rates of in-hospital complications, in addition to the relatively young age of our patients. The in-hospital mortality (5.3%) was comparable to other registries, with mortality ranging from 3.8 to 7.7%, 12 -18 but a direct comparison should be drawn with caution in view of some of the differences in the clinical features of other AHF populations. In addition, exclusion criteria were implemented in other registries, such as the exclusion of patients with ACS in the ATTEND registry. 18 Regarding HCHF, our focus in this report was to describe the clinical, diagnostic, and therapeutic features upon admission to the HFC. No unified standard design exists, that is, accepted internationally for HFCs. Some clinics include all HF patients, regardless of symptom severity. 25 Other clinics, like ours, manage only HCHF patients who are at an increased risk for hospital re-admission and/ or mortality, 26 which is evident from the fact that 59% of our HFC patients were NYHA class III/IV and 75.3% had moderate/severe LV dysfunction compared with 27 and 63.9% in the ESC-HF Pilot survey, respectively. 23 The high rate (45%) of idiopathic dilated cardiomyopathy in our HCHF patients is likely related to the practice pattern of the referring cardiologists who prefer to continue following patients with ischaemic cardiomyopathy in their clinics and tend to refer patients with an unclear diagnosis for further work-up/management in the HFC. Continued education of the hospital staff about the benefit of the HFC will hopefully reduce this referral bias in the future. The rate of use of evidence-based therapies in this patient cohort was satisfactory. Beta-blockers, ACE-I/ARBs, and aldosterone antagonists were used in 95, 86, and 53% of patients, respectively, use in the ESC-HF Pilot survey was 86.7, 88.5, and 43.7%, respectively. 23 This high-usage rate in our HFC is likely related to the fact that the clinics were conducted in two major tertiary care hospitals, and they were accepting referrals for 'the sickest of the sick' HF patients who, in most cases, were already managed by a cardiologist. Implantable cardioverter defibrillator and CRT devices were used in 29 and 8% of patients, respectively, on entry to the HFC. These rates are relatively suboptimal as almost three-quarters of our patients had moderate/ severe LV dysfunction.
Limitations
As with most other registries, hospital enrolment was voluntary; thus, the study results may not be representative of clinical practice in all hospitals in the country. In addition, hospitals that participated in the registry might be more enthusiastic about adherence to guidelines and quality improvement initiatives. An inherent selection bias is present because of the observational nature of the study design. The inclusion criteria of our HFC may not have captured all high-risk patients with HF, and there may have been a selection bias by including only outpatients who were living inside the city area. However, this is the first time that a multicentre national programme has been initiated for HCHF patients in our country. Furthermore, the small sample size recruited from a few tertiary care hospitals results in a limited representation of care in our country. However, the aim of this report was to describe the overall design of the study in addition to the preliminary results of the pilot phase.
Conclusions
HEARTS is the first multicentre HF registry and quality improvement initiative in the Kingdom of Saudi Arabia and the Arab population. We showed that our HF patients present at a relatively young age, have extremely high rates of diabetes mellitus compared with patients in developed countries, and predominantly have LV systolic dysfunction, mainly of ischaemic aetiology. The preliminary results of the study show potential targets for improvement in care, such as ICD/CRT device implantation in HCHF patients. Our aim in the future is to include more secondary and tertiary care hospitals in the next phase of the registry to more widely represent HF care in our country.
